Directory › Eurofins BioPharma Product Testing

Eurofins BioPharma Product Testing — North York

North York, Canada · Testing lab

This is a record of what regulators published, not a rating.

Site facts

Company
Eurofins BioPharma Product Testing
Name(s) in FDA data
Eurofins BioPharma Product Testing Toronto, Inc.
FEI number(s)
3002996761 (present in FDA Data Dashboard records for this name and city)
Location (as in FDA data)
North York, Canada
Records matched
4 FDA inspections · 1 inspection with posted 483 citations
Most recent FDA inspection in dataset
15 Nov 2023 — NAI

Capabilities (from the company's website)

  • Analytical testing
    …and NAT Small molecules Supporting your facility Services that span risk identification, method development, sampling, analytical validation, and ongoing monitoring Disinfectant validation ensures…
  • Microbiology
    …agents are fit for purpose and that your facility is safe for production. A full suite of environmental monitoring services designed to be as rigorous, responsive, and reliable as your cleanroom demands.…

Taken from a company-level page; the company does not publish a separate page for this site, so tags may describe the wider organisation. Source: https://www.eurofins.com/en/biopharma-services/biopharma-product-testing/, checked 16 Oct 2026. Quoted text shows the wording each tag is based on.

Regulatory timeline

Newest first. Each entry links to the published source. Inspection classifications: NAI = no action indicated, VAI = voluntary action indicated, OAI = official action indicated (FDA definitions). Posted 483 citations are FDA's short summaries, not the full Form 483.

  1. 15 Nov 2023
    FDA inspection FDA inspection classified NAI

    No Action Indicated (NAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3002996761, inspection ID 1225652)

  2. 15 Nov 2019
    Form 483 observations 3 posted Form 483 citation(s)

    Citation summaries (3)
    • 21 CFR 211.192: Written record of investigation incomplete
    • 21 CFR 211.194(a): Complete test data included in records
    • 21 CFR 211.22(d): Procedures not in writing, fully followed

    Source: FDA Data Dashboard – Citations (FEI 3002996761, inspection ID 1110749)

  3. 15 Nov 2019
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs, Veterinary. Project area(s): Drug Quality Assurance; Monitoring of Marketed Animal Drugs, Feed, and Devices.

    Source: FDA Data Dashboard – Inspections (FEI 3002996761, inspection ID 1110749)

  4. 19 Feb 2016
    FDA inspection FDA inspection classified NAI

    No Action Indicated (NAI). Product type(s): Drugs, Veterinary. Project area(s): Drug Quality Assurance; Monitoring of Marketed Animal Drugs, Feed, and Devices.

    Source: FDA Data Dashboard – Inspections (FEI 3002996761, inspection ID 967934)

  5. 27 Mar 2012
    FDA inspection FDA inspection classified NAI

    No Action Indicated (NAI). Product type(s): Drugs, Veterinary. Project area(s): Drug Quality Assurance; Monitoring of Marketed Animal Drugs, Feed, and Devices.

    Source: FDA Data Dashboard – Inspections (FEI 3002996761, inspection ID 776652)

This is a record of what regulators published, not a rating. Absence of a record here does not mean no record exists; see methodology for what we check and how records are matched.